Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,465.89
(
0.35%
)
News Focus
News Focus
Post# of 257483
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122925
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: marthambles post# 217691

Monday, 03/05/2018 10:58:21 AM

Monday, March 05, 2018 10:58:21 AM

Post# of 257483

RVNC—...the Mylan deal is a net positive if you believe a biosimilar would have entered the market in any event.

Undoubtedly; however, I'm not convinced that any of the companies focusing on FoBs could have accomplished such a feat without RVNC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today